Cargando…

Early response to upfront neoadjuvant chemotherapy (CAPOX) alone in low- and intermediate-risk rectal cancer: a single-arm phase II trial

BACKGROUND: With local recurrence of rectal cancer continuing to decrease, distant recurrence is becoming a major concern, especially for patients with low- and intermediate-risk stage II/III rectal cancer. Therefore, a new treatment strategy is warranted for these patients. This single-arm phase II...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Xiangbing, Wu, Qingbin, Bi, Liang, Yu, Yongyang, Huang, Shuo, He, Du, Wu, Bing, Gou, Hongfeng, Meng, Wenjian, Qiu, Meng, He, Yazhou, Wang, Ziqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364694/ https://www.ncbi.nlm.nih.gov/pubmed/34792107 http://dx.doi.org/10.1093/bjs/znab388

Ejemplares similares

Comparison of the pathological response to 2 or 4 cycles of neoadjuvant CAPOX in II/III rectal cancer patients with low/intermediate risks: study protocol for a prospective, non-inferior, randomized control trial (COPEC trial)
por: Shen, Yu, et al.
Publicado: (2023)

Predicting Response to Total Neoadjuvant Treatment (TNT) in Locally Advanced Rectal Cancer Based on Multiparametric Magnetic Resonance Imaging: A Retrospective Study
por: Ouyang, Ganlu, et al.
Publicado: (2021)

Predicting Rectal Cancer Response to Total Neoadjuvant Treatment Using an Artificial Intelligence Model Based on Magnetic Resonance Imaging and Clinical Data
por: Ouyang, Ganlu, et al.
Publicado: (2023)

Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial
por: Chen, Xiaorong, et al.
Publicado: (2023)

Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)
por: Wang, Yaqi, et al.
Publicado: (2022)

Adding Three Cycles of CAPOX after Neoadjuvant Chemoradiotherapy Increases the Rates of Complete Response for Locally Advanced Rectal Cancer
por: Zhai, Zhiwei, et al.
Publicado: (2021)

CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial
por: Liu, Fangqi, et al.
Publicado: (2016)

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
por: Snoeren, Nikol, et al.
Publicado: (2010)

Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H/dMMR rectal cancer: A prospective, multicenter, phase Ib study
por: Li, Xiaofen, et al.
Publicado: (2022)

A novel hand-assisted laparoscopic versus conventional laparoscopic right hemicolectomy for right colon cancer: study protocol for a randomized controlled trial
por: Yang, Xuyang, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial
por: Mei, Wei-Jian, et al.
Publicado: (2023)

Adjuvant Chemotherapy after Neoadjuvant Chemotherapy and Long-term Outcomes of CAPOX Plus Bevacizumab Followed by TME for High-risk Localized Rectal Cancer
por: Nishimura, Junichi, et al.
Publicado: (2020)

Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial
por: He, Yazhou, et al.
Publicado: (2015)

Impact of Upfront Chemotherapy on the Effect of Primary Tumour Resection for Asymptomatic Synchronous Colorectal Cancer With Unresectable Metastases: A Propensity-Score-Matched Cohort Analysis
por: Huang, Lin, et al.
Publicado: (2022)

The effect of BMI on long-term outcome in patients with rectal cancer and establishment of a nomogram prediction model
por: Zhang, Yang, et al.
Publicado: (2023)

The impact of general/visceral obesity on completion of mesorectum and perioperative outcomes of laparoscopic TME for rectal cancer: A STARD-compliant article
por: Chen, Bingchen, et al.
Publicado: (2016)

Pelvic peritoneum reconstruction using the bladder peritoneum flap in laparoscopic extralevator abdominoperineal excision: A multi-center, prospective single-arm cohort study (IDEAL Phase 2A)
por: Shen, Yu, et al.
Publicado: (2020)

Impact of XRCC2 Arg188His Polymorphism on Cancer Susceptibility: A Meta-Analysis
por: He, Yazhou, et al.
Publicado: (2014)

The effect of pericolic lymph nodes metastasis beyond 10 cm proximal to the tumor on patients with rectal cancer
por: Yang, Xuyang, et al.
Publicado: (2020)

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation
por: Wu, Jingjing, et al.
Publicado: (2023)

Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II)
por: Hattori, Norifumi, et al.
Publicado: (2019)

Clinical significance of the EMD/mesorectum ratio of T3 mid-low rectal cancer: A retrospective observational study
por: Gu, Chaoyang, et al.
Publicado: (2018)

The prognostic significance of MRI-detected extramural venous invasion, mesorectal extension, and lymph node status in clinical T3 mid-low rectal cancer
por: Gu, Chaoyang, et al.
Publicado: (2019)

Lateral pelvic lymph node dissection after neoadjuvant chemo-radiation for preoperative enlarged lateral nodes in advanced low rectal cancer: study protocol for a randomized controlled trial
por: Wei, Mingtian, et al.
Publicado: (2016)

Comment on “Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial” by Mei et al.: Two Overtreatments Compared
por: Mroczkowski, Paweł
Publicado: (2023)

Prognostic role of the lymphocyte-to-monocyte ratio in colorectal cancer: An up-to-date meta-analysis
por: Wu, Qingbin, et al.
Publicado: (2017)

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
por: Ono, Kosuke, et al.
Publicado: (2021)

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2022)

Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients
por: Zhao, Ying, et al.
Publicado: (2017)

Survival outcomes of stage I colorectal cancer: development and validation of the ACEPLY model using two prospective cohorts
por: Wu, Qingbin, et al.
Publicado: (2023)

MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison
por: Zhang, Zhiwen, et al.
Publicado: (2023)

Neoadjuvant therapy or upfront surgery in advanced endometrial cancer: a systematic review protocol
por: McCarthy, Amy, et al.
Publicado: (2021)

The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer
por: Zwart, Eline S., et al.
Publicado: (2023)

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)

Do inflammatory markers predict prognosis in patients with synchronous colorectal cancer?
por: He, Wanbin, et al.
Publicado: (2017)

Laparoscopic versus conventional open surgery in T4 rectal cancer: A case–control study
por: Zhang, Xubing, et al.
Publicado: (2019)

Could the arm blood pressure measured with simultaneous bilateral arm method be used for hypertension diagnosis?
por: Wan, Taixuan, et al.
Publicado: (2020)

Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
por: Dewdney, A, et al.
Publicado: (2012)

Can patients with good tumor regression grading after neoadjuvant chemoradiotherapy be exempted from lateral lymph node dissection?
por: Liu, Xianwei, et al.
Publicado: (2022)

The diagnostic value of exosomal circular RNAs in cancer patients: A systematic review and meta‐analysis
por: Zhang, Yang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_12ahpcko3qp3q94dhnse617pkr